Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MultiStem Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

Next Previous
Trial Profile

MultiStem Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 27 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Invimestrocel (Primary)
  • Indications Ischaemic stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms MASTERS-2
  • Sponsors Athersys; Healios

Most Recent Events

  • 10 Oct 2023 Results presented in an Athersys Media Release.
  • 10 Oct 2023 According to an Athersys media release, company concluded current sample size of 300 patients is insufficiently powered to achieve primary endpoint of mRS Shift analysis at Day 365.There were no safety issues identified.Because sample size required to achieve statistical significance is considerably larger, company intends to conduct additional data analysis with independent statisticians and plans to pause enrollment of new patients while this analysis is being conducted.
  • 10 Oct 2023 Status changed to suspended, according to an Athersys media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top